Amgen reported positive results from its phase 3 trials of its thyroid eye disease treatment.
The biotechnology company said Monday that its under-the-skin version of Tepezza met its primary endpoints in treating moderate-to-severe thyroid eye disease, showing a 77% proptosis response rate, where there is a forward bulging of the eye, during the 24-week placebo-controlled period.
Thyroid eye disease is a rare autoimmune condition in which the body's immune system mistakenly attacks the tissues around the eyes.
Amgen said the effects of the subcutaneous version of the drug showed comparable results to the intravenous form of the medication.
Additionally, the company said the subcutaneous trial also showed strong improvements across many secondary measures of the disease, such as improvement for patients with double vision, called diplopia.
On the safety performance front, the company said the overall results were similar to its IV version.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.